Researchers have long speculated that aromatase inhibitors (AIs), a class of drugs used to treat estrogen-driven breast cancer, could also prevent development of the disease in older women. New research presented at the annual San Antonio Breast Cancer Symposium this past December confirms that suspicion.
Results of the IBIS-II Prevention trial showed that after a median follow-up of five years, postmenopausal women at high risk for breast cancer who take the AI anastrozole could reduce their risk of developing the disease by half, which means that 2 percent of women on anastrozole would develop breast cancer over five years compared with 4 percent of women on the placebo. However, it is unknown if the AI can actually prevent deaths from breast cancer.
Participants who took anastrozole experienced a modest increase in musculoskeletal events.
Researchers were surprised to find that women taking anastrozole also experienced a reduction in developing other malignancies, such as skin, gastrointestinal and gynecologic cancers.
AIs work by blocking the enzyme aromatase from converting the hormone androgen into estrogen, but they can slightly increase the risk of muscle and joint pain, as well as bone mineral loss.
Extending Healing Commitment to a Cancer Community
April 30th 2024It is Meaghan’s unwavering dedication to supporting children and families during a parent’s illness, along with her willingness to take her direct patient care to practices within her professional position and her community service, that allow me to say Meaghan is truly an extraordinary healer deserving of this honor.
Read More
The Essence of Remarkable Cancer Care
April 29th 2024This year marks the 18th year that CURE and Oncology Nursing News have hosted the Extraordinary Healer Award for Oncology Nursing, which gives people the opportunity to recognize and honor the oncology nurses who have made a significant impact on their life.
Read More